Isoniazid prevention of HIV-associated tuberculosis

The Lancet Infectious Diseases

Volumn 13, Issue 10, 2013, Pages 825-827

  Rangaka, Molebogeng Xheedha ^a,b,e   Wilkinson, Robert John ^a,c,d,e  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ISONIAZID;

ANTIVIRAL THERAPY; DRUG EFFICACY; FOLLOW UP; HEALTH CARE QUALITY; HEALTH SERVICE; HIV ASSOCIATED TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LETTER; MORTALITY; PRIORITY JOURNAL; SCREENING TEST; SOCIOECONOMICS; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; FEMALE; HIV INFECTIONS; HUMANS; ISONIAZID; MALE; TUBERCULOSIS;

EID: 84884417859     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70218-4     Document Type: Letter

References (12)

1. Durovni B, Saraceni V, Moulton LH, et al. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis 2013, published online Aug 16. http://dx.doi.org/10.1016/S1473-3099(13)70187-7.
2. Paim J, Travassos C, Almeida C, Bahia L, Macinko J The Brazilian health system: history, advances, and challenges. Lancet 2011, 377:1778-1797.
3. Victora CG, Barreto ML, do Carmo Leal M, et al. Health conditions and health-policy innovations in Brazil: the way forward. Lancet 2011, 377:2042-2053.
4. Kirkwood BR, Cousens SN, Victora CG, de Zoysa I Issues in the design and interpretation of studies to evaluate the impact of community-based interventions. Trop Med Int Health 1997, 2:1022-1029.
5. Habicht JP, Victora CG, Vaughan JP Evaluation designs for adequacy, plausibility and probability of public health programme performance and impact. Int J Epidemiol 1999, 28:10-18.
6. Barreto ML, Teixeira MG, Bastos FI, Ximenes RA, Barata RB, Rodrigues LC Successes and failures in the control of infectious diseases in Brazil: social and environmental context, policies, interventions, and research needs. Lancet 2011, 377:1877-1889.
7. Akolo C, Adetifa I, Shepperd S, Volmink J Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database of Syst Rev 2010, 1. CD000171.
8. Wilkinson KA, Seldon R, Meintjes G, et al. Dissection of regenerating T-cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis. Am J Respir Crit Care Med 2009, 180:674-683.
9. Churchyard G, Fielding K, Lewis J, et al. Community-wide isoniazid preventive therapy does not improve tb control among gold miners: the Thibela TB study, South Africa. 19th Conference on Retroviruses and Opportunistic Infections; Seattle WA, USA; March 5-8, 2012. Abstract 150aLB.
10. Ayles H, and the ZAMSTAR Study Team. A household-based HIV and TB intervention increases HIV testing in households and reduces prevalence of TB at the community level: the ZAMSTAR community randomized trial. 19th Conference on Retroviruses and Opportunistic Infections; Seattle WA, USA; March 5-8, 2012. Abstract 149bLB.
11. Fielding K, Grant A, Lewis J, Hayes R, Churchyard G. Individual-level effect of isoniazid preventive therapy of risk of TB: the Thibela study. 19th Conference on Retroviruses and Opportunistic Infections; Seattle WA, USA; March 5-8, 2012. Abstract 150bLB.
12. Samandari T, Agizew T, Nyirenda S, et al. TB incidence increase after cessation of 36 months' isoniazid prophylaxis in HIV+ adults: Botswana. 19th Conference on Retroviruses and Opportunistic Infections; Seattle WA, USA; March 5-8, 2012. Abstract 147.